{
    "nct_id": "NCT05304377",
    "official_title": "A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia",
    "inclusion_criteria": "* BCR-ABL1 positive CML in chronic phase, with or without T315I mutation.\n* The patient has failed, is intolerant to, or not a candidate for, available therapies known to be active for treatment of their CML.\n* ECOG performance status of 0 to 2.\n* Adequate hematologic, hepatic and renal function.\n* Prior bone marrow transplant allowed if â‰¥ 6 months prior to the first dose of ELVN-001.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Treatment with anti-cancer or anti-CML therapy within 7 days or 5 half-lives, whichever is longer.\n* History of acute tyrosine kinase inhibitor (TKI)-related pancreatitis within 6 months of study entry. Active chronic pancreatitis, or pancreatic disease due to any cause.\n* QTc >470 ms.",
    "miscellaneous_criteria": ""
}